Sagimet Biosciences (NASDAQ: SGMT) Progresses Denifanstat in Key Phase 3 Acne Trial
Key points
- Sagimet Biosciences is advancing denifanstat, an oral treatment for moderate to severe acne, into a crucial U.S. Phase 3 clinical trial.
- Positive Phase 3 results from its license partner in China suggest potential efficacy, raising expectations for the ongoing U.S. study.
- With an estimated 10 million Americans suffering from moderate to severe acne, denifanstat targets a substantial market, offering significant growth potential for Sagimet Biosciences.
The biotech firm, Sagimet Biosciences (NASDAQ: SGMT), is a drug developer actively testing denifanstat as an oral treatment for moderate to severe acne. H.C. Wainwright maintains its Buy rating on the stock, though a recent update listed the action as “hold.” The stock currently trades at $9.72 when this update is posted.
Sagimet Biosciences recently announced that the first patient has received a dose in AURORA, its U.S. Phase 3 trial for denifanstat. This pivotal study aims to enroll approximately 800 patients, including 450 adolescents, and is designed to support a U.S. application for regulatory approval. Notably, Sagimet Biosciences’ license partner, Ascletis, has already reported positive Phase 3 results for denifanstat in China, providing encouraging data for the drug’s potential.
A key question for investors and the medical community is whether the U.S. trial will produce similar positive results, a point highlighted by Seeking Alpha’s analysis. The analysis further notes that the denifanstat trial is fully funded and emphasizes the drug’s potential advantages for long-term acne treatment. Sagimet Biosciences estimates that about 10 million Americans suffer from moderate to severe acne, indicating a large potential market for denifanstat if it gains approval.
Currently, Sagimet Biosciences stock trades at $9.77, reflecting a decrease of $0.22, or 2.20%, today. Its intraday price has ranged from $9.67 to $10.19, compared with a 52-week range of $4.50 to $11.45. The company’s market capitalization, a key indicator of its size, stands at approximately $318.30 million, based on its outstanding shares. Trading volume for the day is 259,171 shares.
Read the rest, free
Pop in your email to read every article in full and search any company. It takes five seconds.
You'll get Gro's newsletter too. Leave any time in one click.
